Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIMOLIDE 10-25 vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Timolol is extensively metabolized in the liver primarily by CYP2D6; hydrochlorothiazide is not metabolized and is excreted unchanged in urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Timolol is approximately 10-60% bound to plasma proteins (primarily albumin). Hydrochlorothiazide is about 40-70% bound to plasma proteins.
~20% bound to albumin; minimal binding to other plasma proteins.
Timolol: Vd approximately 1.3-3.6 L/kg, indicating extensive tissue distribution. Hydrochlorothiazide: Vd approximately 0.8-1.2 L/kg.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral bioavailability of timolol is approximately 50-75% due to first-pass metabolism. Hydrochlorothiazide bioavailability is about 65-70%. Ophthalmic timolol undergoes systemic absorption, with measurable plasma levels.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-50 m L/min: maximum dose of timolol 10 mg/hydrochlorothiazide 25 mg once daily. GFR <30 m L/min: contraindicated (hydrochlorothiazide ineffective, risk of thiazide accumulation).
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose; start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg) and titrate cautiously. Child-Pugh C: contraindicated (risk of hepatic encephalopathy and beta-blocker toxicity).
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended; safety and efficacy not established in pediatric patients.
Not recommended; inadequate safety data.
Start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg once daily); monitor renal function, electrolytes, and heart rate. Avoid in patients with significant bradycardia or heart block.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
No FDA black box warning.
None
Exacerbation of angina or myocardial ischemia upon abrupt withdrawal,Bronchospasm in patients with asthma or COPD,Masking of hypoglycemia in diabetic patients,Electrolyte imbalances, hypokalemia, hypercalcemia, hyperuricemia due to hydrochlorothiazide,Fetal harm if used during pregnancy
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Overt cardiac failure,Anuria,Hypersensitivity to timolol or hydrochlorothiazide
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-potassium foods (e.g., bananas, oranges, potatoes) as hydrochlorothiazide can cause potassium loss, but timolol may mask hyperkalemia. Limit salt intake to enhance blood pressure control. Consume alcohol moderately as it may potentiate hypotension. Take with food to reduce gastrointestinal upset.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. Thiazides may cause fetal electrolyte imbalances and jaundice. Second and third trimesters: Continued risk of fetal bradycardia, reduced placental perfusion, and neonatal complications (hypoglycemia, bradycardia, respiratory depression). Thiazides may cause oligohydramnios and neonatal thrombocytopenia.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Timolol is excreted into breast milk (M/P ratio approximately 1.4). Hydrochlorothiazide is also present in low amounts. Due to potential for infant bradycardia, hypoglycemia, and electrolyte disturbances, use during breastfeeding is generally not recommended. If essential, monitor infant for signs of beta-blockade and thiazide effects.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pregnancy may alter pharmacokinetics of timolol due to increased plasma volume and renal clearance. Hydrochlorothiazide efficacy may be reduced due to increased GFR. Dose adjustments should be guided by clinical response but no standard dose modification; use lowest effective dose.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Timolide 10-25 contains timolol (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor heart rate and blood pressure closely due to risk of bradycardia and hypotension. Avoid abrupt discontinuation to prevent rebound hypertension. Use with caution in patients with asthma, COPD, or diabetes as beta-blockers can mask hypoglycemia. Check electrolytes and renal function periodically due to diuretic effects.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this drug suddenly; consult your doctor before discontinuing to avoid a rapid rise in blood pressure.,Notify your doctor if you experience slow heartbeat, dizziness, fainting, or signs of electrolyte imbalance (e.g., muscle cramps, weakness, irregular heartbeat).,Avoid alcohol as it may increase dizziness or drowsiness.,Use caution when driving or operating machinery until you know how this medication affects you.,Keep all appointments for blood pressure and lab tests (e.g., potassium, sodium, kidney function).
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIMOLIDE 10-25 vs ALDORIL D50, answered by our medical review team.
TIMOLIDE 10-25 is a Antihypertensive Combination that works by Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIMOLIDE 10-25 and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIMOLIDE 10-25 is: One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIMOLIDE 10-25 and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIMOLIDE 10-25 is classified as Category C. First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. T. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.